DPA-714-PET/MRI

Phase 1Small molecule

DPA-714-PET/MRI is one of 81 small molecule programs targeting Severe Acute Respiratory Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Acute Respiratory SyndromeActive, not recruiting

Myocardial InfarctionActive, not recruiting

Severe Acute Respiratory SyndromePhase 1

Active, not recruiting

Myocardial InfarctionPhase 1

Active, not recruiting

Competition

Competitive Landscape

232 competitors in Myocardial Infarction

#DrugCompanyPhaseTrials

Reopro

Boehringer Ingelheim

Phase 3

4 2

Aggrastat

MMedicure

Phase 3

1 3

Ticlid

Roche

Phase 3

1 4

Tissue Plasminogen Activator

NNeuroscience Trials Australia

Phase 3

2 5

Actilyse

Boehringer Ingelheim

Phase 3

1 6

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

1 7

Prasugrel Loading Dose

Daiichi Sankyo

Phase 3

1 8

Octagam

OOslo University Hospital

Phase 3

1 9

Dutogliptin Tartrate

RRecardio, Inc.

Phase 3

2 10

Repatha

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Carotid Stenosis

NCT05850247

Q2 2027

Phase 1/2Recruiting

Parkinson's Disease

NCT03457493

Q2 2028

Phase 1Recruiting

Neuroinflammation

NCT03759522

Phase 1Recruiting

Severe Acute Respiratory Syndrome

NCT05656105

Q4 2028

Phase 1Active, not recruiting

Myocardial Infarction

NCT03968445

Clinical

Trials by Indication[1]

Neuroinflammation1 trial

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT03759522·120 enrolled

Myocardial Infarction1 trial

Neuroinflammation After Myocardial Infarction - Imaging Substudy

Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT03968445·6 enrolled

Carotid Stenosis1 trial

Plaque and Brain Inflammation in Symptomatic Carotid Stenosis: Role of the Ficolin-2

Recruiting·HHospices Civils de Lyon·Phase 2·NCT05850247·20 enrolled

Parkinson's Disease1 trial

The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

Recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT03457493·205 enrolled

Severe Acute Respiratory Syndrome1 trial

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT05656105·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for DPA-714-PET/MRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DPA-714-PET/MRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DPA-714-PET/MRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Alabama at Birmingham

DPA-714-PET/MRI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Neuroinflammation1 trial

Myocardial Infarction1 trial

Carotid Stenosis1 trial

Parkinson's Disease1 trial

Severe Acute Respiratory Syndrome1 trial

References

Drug Info

Quick Facts

Related News